Related Experiment Video
Updated: Apr 21, 2026
![Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F58641.jpg&w=3840&q=50)
Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury
Published on: November 9, 2018
Glucose uptake of the spinal cord in patients with multiple sclerosis detected by ¹⁸F-fluorodeoxyglucose PET/CT after
J H Kindred1, P J Koo2, T Rudroff1
1Department of Health and Exercise Science, Colorado State University, Fort Collins, CO, USA.
Study Design:
Case report.
Objectives:
To determine [(18)F]-fluorodeoxyglucose ([(18)F]-FDG) uptake in the spinal cord of patients with multiple sclerosis (MS) was compared with healthy controls after treadmill walking.
Setting:
Colorado Translational Research Imaging Center, University of Colorado School of Medicine, Aurora, CO, USA.
Methods:
Eight mildly disabled patients with MS and eight healthy subjects performed 15 min of treadmill walking at a self-selected pace. Two minutes after walking began, each participant was injected with ≈8 mCi of [(18)F]-FDG into a catheter inserted into an antecubital vein. Immediately after walking positron emission tomography/computed tomography (PET/CT) imaging was performed on each participant. Images were analyzed to determine [(18)F]-FDG uptake within the spinal cord.
Results:
Total spinal cord [(18)F]-FDG uptake was lower in patients with MS (1.48±0.36 and 1.55±0.33, P=0.04), specifically within the thoracic (1.32±0.27 and 1.41±0.24, P<0.01) and the lumbar (1.58±0.40 and 1.89±0.43, P=0.04) spinal cord regions.
Conclusion:
This is the first report of [(18)F]-FDG uptake in the spinal cord of patients with MS. The decreased [(18)F]-FDG uptake within the thoracic and lumbar spinal cord regions could be associated with autonomic nervous system and walking/motor dysfunctions that are often seen in patients with MS. PET/CT imaging with [(18)F]-FDG is highly useful for the demonstration of impaired glucose metabolism in the spinal cord of patients with MS.
